Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Yoon

Showing results (1011-1020 of 1,104) with videos related to

Pageof 111
Sort By:
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Experimental & Molecular Medicine|November 3, 2022
A database of 5305 healthy Korean individuals reveals genetic and clinical implications for an East Asian populationJeongeun Lee, Jean Lee, Sungwon Jeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Nature Communications|March 30, 2024
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trialChanghee Park, Ho Sup Lee, Ka-Won Kang, et al.
Blood|June 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
Annals of Hematology|March 30, 2010
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safetySung Sook Lee, Cheolwon Suh, Bong-Seog Kim, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2021
Clinical characteristics and prognostic factors of acquired haemophilia A in KoreaShin Young Hyun, Ho-Jin Shin, Sung-Soo Yoon, et al.
Pageof 111

Showing results (1011-1020 of 1,104) with videos related to

Sort By:
Pageof 111
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Experimental & Molecular Medicine|November 3, 2022
A database of 5305 healthy Korean individuals reveals genetic and clinical implications for an East Asian populationJeongeun Lee, Jean Lee, Sungwon Jeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Nature Communications|March 30, 2024
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trialChanghee Park, Ho Sup Lee, Ka-Won Kang, et al.
Blood|June 12, 2026
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01)Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
Annals of Hematology|March 30, 2010
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safetySung Sook Lee, Cheolwon Suh, Bong-Seog Kim, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2021
Clinical characteristics and prognostic factors of acquired haemophilia A in KoreaShin Young Hyun, Ho-Jin Shin, Sung-Soo Yoon, et al.
Pageof 111